262 related articles for article (PubMed ID: 32829387)
1. Systematic molecular and clinical analysis of uterine leiomyomas from fertile-aged women undergoing myomectomy.
Äyräväinen A; Pasanen A; Ahvenainen T; Heikkinen T; Pakarinen P; Härkki P; Vahteristo P
Hum Reprod; 2020 Oct; 35(10):2237-2244. PubMed ID: 32829387
[TBL] [Abstract][Full Text] [Related]
2.
Heikkinen T; Äyräväinen A; Hänninen J; Ahvenainen T; Bützow R; Pasanen A; Vahteristo P
Hum Reprod Open; 2018; 2018(4):hoy020. PubMed ID: 30895261
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs involved in the HMGA2 deregulation and its co-occurrence with MED12 mutation in uterine leiomyoma.
Mello JBH; Barros-Filho MC; Abreu FB; Cirilo PDR; Domingues MAC; Pontes A; Rogatto SR
Mol Hum Reprod; 2018 Nov; 24(11):556-563. PubMed ID: 30376129
[TBL] [Abstract][Full Text] [Related]
4. MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.
Kämpjärvi K; Mäkinen N; Mehine M; Välipakka S; Uimari O; Pitkänen E; Heinonen HR; Heikkinen T; Tolvanen J; Ahtikoski A; Frizzell N; Sarvilinna N; Sjöberg J; Bützow R; Aaltonen LA; Vahteristo P
Br J Cancer; 2016 Jun; 114(12):1405-11. PubMed ID: 27187686
[TBL] [Abstract][Full Text] [Related]
5. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
6. 3'RNA and whole-genome sequencing of archival uterine leiomyomas reveal a tumor subtype with chromosomal rearrangements affecting either HMGA2, HMGA1, or PLAG1.
Jokinen V; Mehine M; Reinikka S; Khamaiseh S; Ahvenainen T; Äyräväinen A; Härkki P; Bützow R; Pasanen A; Vahteristo P
Genes Chromosomes Cancer; 2023 Jan; 62(1):27-38. PubMed ID: 35822448
[TBL] [Abstract][Full Text] [Related]
7. Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers.
Mehine M; Kaasinen E; Heinonen HR; Mäkinen N; Kämpjärvi K; Sarvilinna N; Aavikko M; Vähärautio A; Pasanen A; Bützow R; Heikinheimo O; Sjöberg J; Pitkänen E; Vahteristo P; Aaltonen LA
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1315-20. PubMed ID: 26787895
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of AKT and the related biomarkers in uterine leiomyomas with MED12, HMGA2, and FH mutations.
Xie J; Ubango J; Ban Y; Chakravarti D; Kim JJ; Wei JJ
Genes Chromosomes Cancer; 2018 Oct; 57(10):485-494. PubMed ID: 29790226
[TBL] [Abstract][Full Text] [Related]
9. Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas.
Heinonen HR; Pasanen A; Heikinheimo O; Tanskanen T; Palin K; Tolvanen J; Vahteristo P; Sjöberg J; Pitkänen E; Bützow R; Mäkinen N; Aaltonen LA
Sci Rep; 2017 Apr; 7(1):1015. PubMed ID: 28432313
[TBL] [Abstract][Full Text] [Related]
10. MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
Mäkinen N; Vahteristo P; Kämpjärvi K; Arola J; Bützow R; Aaltonen LA
Eur J Hum Genet; 2013 Nov; 21(11):1300-3. PubMed ID: 23443020
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of somatic and germline mutations of Fumarate hydratase in uterine leiomyomas from young patients.
Liu C; Dillon J; Beavis AL; Liu Y; Lombardo K; Fader AN; Hung CF; Wu TC; Vang R; Garcia JE; Xing D
Histopathology; 2020 Feb; 76(3):354-365. PubMed ID: 31564060
[TBL] [Abstract][Full Text] [Related]
12. Racial differences in transcriptomics and reactive oxygen species burden in myometrium and leiomyoma.
Li Y; McNally RP; Feng Y; Kim JJ; Wei JJ
Hum Reprod; 2023 Apr; 38(4):609-620. PubMed ID: 36749068
[TBL] [Abstract][Full Text] [Related]
13. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma.
Bertsch E; Qiang W; Zhang Q; Espona-Fiedler M; Druschitz S; Liu Y; Mittal K; Kong B; Kurita T; Wei JJ
Mod Pathol; 2014 Aug; 27(8):1144-53. PubMed ID: 24390224
[TBL] [Abstract][Full Text] [Related]
14. MED12 mutation frequency in unselected sporadic uterine leiomyomas.
Heinonen HR; Sarvilinna NS; Sjöberg J; Kämpjärvi K; Pitkänen E; Vahteristo P; Mäkinen N; Aaltonen LA
Fertil Steril; 2014 Oct; 102(4):1137-42. PubMed ID: 25108465
[TBL] [Abstract][Full Text] [Related]
15. Analysis of
Lee M; Cheon K; Chae B; Hwang H; Kim HK; Chung YJ; Song JY; Cho HH; Kim JH; Kim MR
Int J Med Sci; 2018; 15(2):124-128. PubMed ID: 29333096
[TBL] [Abstract][Full Text] [Related]
16. Expression of erythropoietin messenger ribonucleic acid in wild-type MED12 uterine leiomyomas under estrogenic influence: new insights into related growth disparities.
Asano R; Asai-Sato M; Matsukuma S; Mizushima T; Taguri M; Yoshihara M; Inada M; Fukui A; Suzuki Y; Miyagi Y; Miyagi E
Fertil Steril; 2019 Jan; 111(1):178-185. PubMed ID: 30554729
[TBL] [Abstract][Full Text] [Related]
17. Detailed Morphologic and Immunohistochemical Characterization of Myomectomy and Hysterectomy Specimens From Women With Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC).
Chan E; Rabban JT; Mak J; Zaloudek C; Garg K
Am J Surg Pathol; 2019 Sep; 43(9):1170-1179. PubMed ID: 31162287
[TBL] [Abstract][Full Text] [Related]
18. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
[TBL] [Abstract][Full Text] [Related]
19. HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
Galindo LJ; Hernández-Beeftink T; Salas A; Jung Y; Reyes R; de Oca FM; Hernández M; Almeida TA
Gynecol Oncol; 2018 Sep; 150(3):562-568. PubMed ID: 30017537
[TBL] [Abstract][Full Text] [Related]
20. Single-cell sequencing reveals novel cellular heterogeneity in uterine leiomyomas.
Goad J; Rudolph J; Zandigohar M; Tae M; Dai Y; Wei JJ; Bulun SE; Chakravarti D; Rajkovic A
Hum Reprod; 2022 Sep; 37(10):2334-2349. PubMed ID: 36001050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
